quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD)
MK-6482-012, NCT04736706 / 2020-002216-52: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
3
1653
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
10/26
10/26
MK-6482-012 China Extension, NCT05899049: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Active, not recruiting
3
249
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
12/26
12/26
2020-004490-52: Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma

Not yet recruiting
2
110
Europe
MK-1308A (Coformulated MK 1308/MK 3475), Pembrolizumab, Lenvatinib/MK-7902, E7080, Solution for infusion, Capsule, KEYTRUDA® (Pembrolizumab, MK-3475)
Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Advanced hepatocellular carcinoma without any prior systemic treatment., Advanced hepatocellular carcinoma without any prior systemic treatment., Diseases [C] - Cancer [C04]
 
 
2020-005114-18: Phase 2 Basket study of Pembrolizumab or MK1308A in mCRC

Ongoing
2
320
Europe
MK-1308A (Coformulated MK 1308/MK 3475), MK-3475, Solution for infusion, KEYTRUDA® (Pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer, Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
KEYSTEP-008, NCT04895722 / 2020-005114-18: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/)

Active, not recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A, Pembrolizumab/Favezelimab, MK-4280A, Pembrolizumab/Vibostolimab, MK-7684A, MK-4830
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Colorectal Cancer
06/26
06/27
KEYSTEP-004, NCT04740307: Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Active, not recruiting
2
110
Europe, Japan, US, RoW
Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, Pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Hepatocellular Carcinoma
03/26
03/26
2019-003703-35: A Phase 1 /2 Trial of MK-1308 in Subjects with Advanced Solid Tumors

Not yet recruiting
1/2
412
Europe
PEMBROLIZUMAB, MK-1308A (Coformulated MK-1308 / MK-3475), MK-3475, L01XC18, MK-1308, MK-1308A, Solution for infusion, Solution for injection, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Advanced Solid Tumors - first-line, advanced/metastatic NSCLC and second-line (and beyond) advanced/metastatic SCLC, Subjects with advance solid tumor such as those found in the lungs and skin, Diseases [C] - Cancer [C04]
 
 
2019-003610-13: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03B

Not yet recruiting
1/2
370
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-4830, MK-6482, E7080, MK-1308A, MK-4280A, MK-4830, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
2019-003609-84: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A

Not yet recruiting
1/2
430
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-6482, E7080, MK-1308A, MK-4280A, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
2020-003742-36: Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM

Ongoing
1/2
250
Europe
Lenvatinib, MK-1308/Pembrolizumab, E7080, MK-1308A, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
MK-1308-001, NCT03179436: Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors

Checkmark Data from MK-1308-001 trial in combination with pembrolizumab in advanced melanoma
Jun 2022 - Jun 2022: Data from MK-1308-001 trial in combination with pembrolizumab in advanced melanoma
Checkmark Data from MK-1308-001 study in combination with quavonlimab for NSCLC
Oct 2020 - Oct 2020: Data from MK-1308-001 study in combination with quavonlimab for NSCLC
Completed
1/2
413
Europe, Canada, Japan, US, RoW
Quavonlimab, MK-1308, Pembrolizumab, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A
Merck Sharp & Dohme LLC
Advanced Solid Tumors
04/24
04/24
KEYMAKER-U03B, NCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Active, not recruiting
1/2
370
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Favezelimab/Pembrolizumab, MK-4280A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
09/25
09/25
MK-3475-03A, NCT04626479: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma

Active, not recruiting
1/2
400
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Favezelimab/Pembrolizumab, MK-4280A, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Vibostolimab/Pembrolizumab, MK-7684A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
05/26
05/26
KEYNOTE-B98, NCT04938817 / 2020-005628-12: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/)

Recruiting
1/2
110
Europe, Canada, US, RoW
coformulation pembrolizumab/quavonlimab, MK-1308A, lenvatinib, LENVIMA®, KISPLYX®, MK-7902, E7080, MK-4830, coformulation favezelimab/pembrolizumab, MK-4280A, R-DXd
Merck Sharp & Dohme LLC, Daiichi Sankyo
Small Cell Lung Carcinoma
05/26
12/29
KEYMAKER-U02 Substudy 02B, NCT04305054 / 2019-003977-24: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Recruiting
1/2
315
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®, Favezelimab/Pembrolizumab, MK-4280A, ATRA
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck &, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U02 Substudy 02D, NCT04700072 / 2020-003742-36: Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Active, not recruiting
1/2
300
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma
04/30
04/30

Download Options